Transparency Market Research Report Added "Silver Sulfadiazine Market" to its database.
Albany, NY -- (SBWIRE) -- 02/24/2016 -- The World Health Organization pegs the total number of burn-related deaths at 265,000. With burn-related injuries becoming a severe health concern worldwide, the demand for treatment options is also on the rise. The market for silver sulfadiazine will largely benefit from this factor, says Transparency Market Research in its report, titled "Silver Sulfadiazine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020." The report answers key questions about the future of the global silver sulfadiazine market and offers insights into the best and worst performing segments of the market.
Although people in low- and middle-income countries face the highest risk of burn injuries, burn rates are also relatively high in developed economies such as the United States. This has led to a consequent increase in the demand for wound-care products, of which silver sulfadiazine is an important part. The antimicrobial properties of silver have been known to man for many centuries, making wound dressings containing silver common. Silver sulfadiazine is arguably the most widely used product to treat burn injuries. The use of silver sulfadiazine is especially high in North America – a region which also stands as the largest consumer and producer of anti-burn products.
Get Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3956
The report notes that the United States is a leading regional market for silver sulfadiazine. The country sets aside appreciable funds each year to develop treatments for burn wounds. This has boosted the market for silver sulfadiazine in the United States. However, the same cannot be said of the Asia Pacific silver sulfadiazine market, which still remains relatively unexplored.
However, factors that work against the projected growth of the silver sulfadiazine market are as follows: the compound can cause side effects such as dizziness, nausea, and appetite loss. Medical practitioners recommend pregnant women and infants against the use of silver sulfadiazine in view of these side effects. The market will also lose out on growth opportunities because of the ongoing debate about how safe it is to use silver-sulfadiazine-based products. The prices of silver are rising as well and are expected to further hurt the market's growth. This is compounded by the availability of other substitutes such as the xenogeneic tissue scaffold, endovascular arterial repair techniques, bilayered human dermal substitutes, and hyperbaric oxygen therapy. The market is expected to post a steady growth rate despite the many reported harmful effects of silver sulfadiazine market.
Some of the leading companies in the global silver sulfadiazine market are: Johnson & Johnson Limited, Baxter International Inc., 3M Company, Teva Pharmaceutical Industries Ltd., and Monarch Pharmaceuticals.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453